MiMedx Group Inc
MDXG
NASDAQ
Biotechnology
$4.27
USD
+0.07 (+1.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $612.19M
Volume 974.8K
Revenue
$355.17M
TTM
-2.4%
YoY
Gross Margin
79%
TTM
-3.2%
YoY
Net Income
$6.24M
TTM
-80.5%
YoY
Operating Cash Flow
$46.15M
TTM
-20.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 98.6 | 113.7 | 118.1 | 59.0 | 64.4 |
YoY Growth | +13.1% | +35.3% | +27.1% | -33.1% | -34.7% |
Cost of Revenue | 18.7 | 18.7 | 19.1 | 17.4 | 20.0 |
Gross Profit | 79.9 | 95.0 | 99.0 | 41.6 | 44.4 |
Selling, General & Administrative | 64.2 | 69.0 | 73.1 | 53.2 | 59.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 67.6 | 72.8 | 78.0 | 57.7 | 62.8 |
Operating Income | 12.4 | 22.2 | 21.1 | -16.0 | -18.5 |
EBITDA | 15.5 | 27.5 | 24.3 | -14.4 | -16.9 |
Other Income / Expense | -0.1 | -0.1 | -0.2 | -0.2 | -0.1 |
Total Other Income / Expense | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 |
Income Before Income Taxes | 13.0 | 22.8 | 21.8 | -15.3 | -17.8 |
Income Taxes | 3.4 | 6.1 | 6.6 | -4.5 | -2.9 |
Net Income | 9.6 | 16.7 | 15.2 | -10.9 | -14.8 |
Consolidated Net Income / Loss | 9.6 | 16.7 | 15.2 | -10.9 | -14.8 |
Net Income Attributable to Common Shareholders | 9.6 | 16.7 | 15.2 | -10.9 | -14.8 |
Basic EPS | $0.07 | $0.11 | $0.10 | -$0.07 | -$0.10 |
Diluted EPS | $0.06 | $0.11 | $0.10 | $0.00 | -$0.10 |
Basic Shares Outstanding | 147.8M | 148.0M | 148.1M | 148.4M | 147.8M |
Diluted Shares Outstanding | 149.3M | 149.7M | 150.2M | 148.4M | 147.8M |